Cat. No.: HY-116568

Prothioconazole

(Synonyms: JAU-6476)

고객리뷰

Based on 1 Customer Validation

Prothioconazole is an orally active broad-spectrum fungicide. Prothioconazole weakly inhibits CaCYP51 activity in Candida albicans, with an apparent IC₅₀ of approximately 120 μM. Prothioconazole disrupts Microtubule stability by reducing the acetylation level of α-tubulin. Prothioconazole induces Mitochondrial dysfunction, oxidative stress, DNA damage, and Apoptosis. Prothioconazole accumulates ¹⁴-methylated sterols and depletes ergosterol in cells, culture media, plants, and animals. Prothioconazole interferes with pyruvate metabolism and glycolysis/gluconeogenesis processes in mouse liver, downregulates Fasn mRNA expression, and induces hepatotoxicity and renal metabolic disorders. Prothioconazole reduces the fertility of female mice. Prothioconazole inhibits body weight gain and increases liver/kidney indices in mice. Prothioconazole can be used in studies related to candidiasis.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Purity: 99.52%
CAS No.: 178928-70-6
화학식: C₁₄H₁₅Cl₂N₃OS
분자량:344.26

보관:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Prothioconazole Chemical Structure

CAS No.: 178928-70-6

사이즈

가격

재고

수량

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
용액&용해도
- In Vitro
- In Vivo
순도&문서
References
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target^[1]

CYP51

All Cytochrome P450 Isoforms :

All DNA/RNA Synthesis Isoforms :

In Vitro

Prothioconazole shows weak binding affinity to purified *Candida albicans* CaCYP51, with an apparent dissociation constant K_d of 6.3 μM. It generates a type I difference spectrum instead of the typical type II difference spectrum produced by azole antifungal agents^[1].
Prothioconazole (100 μM) competitively inhibits the binding of Lanosterol (HY-W020033) to purified *Candida albicans* CaCYP51, increasing the apparent K_s of Lanosterol by 2.5-fold to 62.2 μM^[1].
Prothioconazole (0-100 μM) weakly inhibits CaCYP51 activity of Candida albicans in a cell-free system, with an apparent IC₅₀ of approximately 120 μM, and only achieves an inhibition rate of 45% at a concentration of 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Prothioconazole (10 mg/kg/day; p.o.; daily; 30 days) exposure in female mice induces reproductive toxicity by disrupting oocyte maturation, fertilization, and early embryo development via mitochondrial dysfunction, oxidative stress, DNA damage, and apoptosis, reducing offspring numbers by ~34%^[2].
Prothioconazole (1-5 mg/kg BW/day; p.o.; daily; 28 days) administration to male ICR mice causes dose-dependent oxidative stress, metabolic disruption, and reduced growth phenotypes, with more severe effects observed in liver tissue compared to kidney tissue^[3].
Prothioconazole (1-5 mg/kg; p.o.; daily; 30 days) induces dose-dependent liver metabolic dysfunction and hepatotoxicity in female ICR mice, disrupting glycolipid metabolism via changes in key gene expression, metabolite levels, and liver histology^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ICR (female, 6-8-week-old)^[2]
Dosage:

1 mg/kg/day; 5 mg/kg/day; 10 mg/kg/day
Administration:

p.o.; daily; 30 days
Result:

Reduced germinal vesicle breakdown (GVBD) rate to 75.3% (control: 89.5%).
Reduced first polar body extrusion (PBE) rate to 48.3% (control: 78.5%).
Reduced number of ovulated oocytes to 39.7 (control: 55.2).
Reduced fertilization rate to 78.5% (control: 95.9%).
Reduced 8-cell embryo rate to 52.6% (control: 63.8%).
Reduced morula rate to 35.1% (control: 61.2%).
Reduced blastocyst rate to 7.2% (control: 36.7%).
Reduced average offspring number to 10.1 (control: 15.3).
Increased aberrant spindle rate to 52.9% (control: 22.2%).
Increased misaligned chromosome rate to 28.6% (control: 15.9%).
Reduced acetylated α-tubulin fluorescence intensity to 15.4 A.U. (control: 32.2 A.U.).
Increased defective kinetochore-microtubule attachments rate to 46.1% (control: 14.3%).
Reduced Juno fluorescence intensity to 24.5 A.U. (control: 34.4 A.U.).
Reduced cortical granule fluorescence intensity to 28.7 A.U. (control: 40.7 A.U.).
Reduced ovastacin fluorescence intensity to 38.7 A.U. (control: 58.7 A.U.).
Reduced sperm binding number to 89.3 per egg (control: 143.8 per egg).
Reduced mitochondrial fluorescence intensity to 18.3 A.U. (control: 27.5 A.U.).
Increased ROS fluorescence intensity to 17.85 A.U. (control: 2.5 A.U.).
Increased γ-H2A.X fluorescence intensity to 21.5 A.U. (control: 13.4 A.U.).
Increased Annexin-V fluorescence intensity to 12.3 A.U. (control: 3.8 A.U.).
Identified 719 downregulated and 528 upregulated differentially expressed genes in oocytes, enriched in pathways related to mitochondrial oxidative phosphorylation, apoptosis, and oocyte meiosis.

Animal Model:

ICR (5-week-old male)^[3]
Dosage:

1 mg/kg BW/day; 5 mg/kg BW/day
Administration:

p.o.; daily; 28 days
Result:

Significantly decreased body weight gain and liver weight at both doses.
Significantly decreased liver index at 1 mg/kg dose; significantly decreased liver index, kidney weight, and kidney index at 5 mg/kg dose.
Did not significantly reduce body weight at either dose.
Significantly decreased glutathione (GSH) content in liver at both doses.
Significantly increased lipid peroxidation (LPO) content, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content in liver at 5 mg/kg dose; did not significantly increase LPO content in liver at 1 mg/kg dose.
Caused no significant changes to catalase (CAT) or peroxidase (POD) activity in liver at either dose.
Caused no significant changes to oxidative stress biomarkers in kidney at either dose.
Significantly increased relative abundances of lipid, lactate, acetate, choline, leucine, glutamate, glutamine, succinate, valine, alanine, lysine, and uracil in liver at both doses; significantly decreased relative abundances of phosphocholine (PC), glycerophosphocholine (GPC), and glycogen in liver at both doses.
Additionally significantly decreased relative abundances of alpha-glucose, beta-glucose, and betaine, and increased relative abundance of taurine in liver at 5 mg/kg dose.
Significantly decreased relative abundance of taurine in kidney at 1 mg/kg dose; significantly increased relative abundances of choline, PC, and glutamine, and decreased relative abundances of lactate, acetate, leucine, taurine, betaine, and succinate in kidney at 5 mg/kg dose.
Significantly altered D-glutamine and D-glutamate metabolism, alanine-aspartate-glutamate metabolism, pyruvate metabolism, and arginine biosynthesis in liver tissue at both doses.
Significantly altered phenylalanine, tyrosine, and tryptophan biosynthesis in kidney tissue at both doses; additionally significantly altered pyruvate metabolism, arginine biosynthesis, and taurine and hypotaurine metabolism in kidney tissue at 5 mg/kg dose.

Chemical Information

CAS No. 178928-70-6
Appearance Solid
분자량 344.26
화학식 C₁₄H₁₅Cl₂N₃OS
Color White to light yellow
SMILES

S=C1NC=NN1CC(CC2=C(Cl)C=CC=C2)(C3(CC3)Cl)O
Synonyms

JAU-6476
선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

용액&용해도

In Vitro:

DMSO : 50 mg/mL (145.24 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9048 mL

14.5239 mL

29.0478 mL

5 mM

0.5810 mL

2.9048 mL

5.8096 mL

10 mM

0.2905 mL

1.4524 mL

2.9048 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

순도&문서

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Parker JE, et al. Prothioconazole and prothioconazole-desthio activities against Candida albicans sterol 14-α-demethylase. Appl Environ Microbiol. 2013;79(5):1639-1645. [Content Brief]

[2]. Zhang M, et al. Prothioconazole exposure disrupts oocyte maturation and fertilization by inducing mitochondrial dysfunction and apoptosis in mice. Free Radic Biol Med. 2024;213:274-284. [Content Brief]

[3]. Meng Z, et al. Effects of exposure to prothioconazole and its metabolite prothioconazole-desthio on oxidative stress and metabolic profiles of liver and kidney tissues in male mice. Environ Pollut. 2021;269:116215. [Content Brief]

[4]. Tian S, et al. Prothioconazole and prothioconazole-desthio induced different hepatotoxicities via interfering with glycolipid metabolism in mice. Pestic Biochem Physiol. 2022;180:104983. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9048 mL	14.5239 mL	29.0478 mL	72.6195 mL
	5 mM	0.5810 mL	2.9048 mL	5.8096 mL	14.5239 mL
	10 mM	0.2905 mL	1.4524 mL	2.9048 mL	7.2620 mL
	15 mM	0.1937 mL	0.9683 mL	1.9365 mL	4.8413 mL
	20 mM	0.1452 mL	0.7262 mL	1.4524 mL	3.6310 mL
	25 mM	0.1162 mL	0.5810 mL	1.1619 mL	2.9048 mL
	30 mM	0.0968 mL	0.4841 mL	0.9683 mL	2.4207 mL
	40 mM	0.0726 mL	0.3631 mL	0.7262 mL	1.8155 mL
	50 mM	0.0581 mL	0.2905 mL	0.5810 mL	1.4524 mL
	60 mM	0.0484 mL	0.2421 mL	0.4841 mL	1.2103 mL
	80 mM	0.0363 mL	0.1815 mL	0.3631 mL	0.9077 mL
	100 mM	0.0290 mL	0.1452 mL	0.2905 mL	0.7262 mL

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent:

상품명:
CAS No.:
Species:
Purity:
수량:

Prothioconazole

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endocrinology Compound Library

Antifungal Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Mitochondria-Targeted Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Protein-protein Interaction Inhibitor Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Pesticide Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Chinese Baijiu Compound Library

High-Efficiency Gene Editing Compound Library

Environmental Pollutant Compound Library

All Cytochrome P450 Isoforms

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

용액&용해도

순도&문서

References

Help & FAQs

Complete Stock Solution Preparation Table

Prothioconazole Related Classifications

HY-116568 Related Classifications